109 related articles for article (PubMed ID: 35639640)
1. Design, Synthesis, and Biological Evaluation of Novel Evodiamine Derivatives as Potential Antihepatocellular Carcinoma Agents.
Lei F; Xiong Y; Wang Y; Zhang H; Liang Z; Li J; Feng Y; Hao X; Wang Z
J Med Chem; 2022 Jun; 65(11):7975-7992. PubMed ID: 35639640
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma.
Fan X; Deng J; Shi T; Wen H; Li J; Liang Z; Lei F; Liu D; Zhang H; Liang Y; Hao X; Wang Z
Bioorg Chem; 2021 Sep; 114():105154. PubMed ID: 34378540
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of guaianolide-germacranolide heterodimers as novel anticancer agents against hepatocellular carcinoma.
Yan JX; Li QH; Li TZ; Huang ZY; Ma YB; Chen JJ
Drug Dev Res; 2023 Sep; 84(6):1285-1298. PubMed ID: 37345274
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and bioactivity evaluation of favorable evodiamine derivative scaffold for developing cancer therapy.
Liang Z; Wang Y; Zhang H; Deng J; Lei F; Li J; Shi T; Wang S; Li R; Wang Z
Eur J Med Chem; 2022 Sep; 239():114530. PubMed ID: 35728506
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma.
Harras MF; Sabour R
Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and bioactivity evaluation of novel evodiamine derivatives with excellent potency against gastric cancer.
Liang Z; Lei F; Deng J; Zhang H; Wang Y; Li J; Shi T; Yang X; Wang Z
Eur J Med Chem; 2022 Jan; 228():113960. PubMed ID: 34774339
[TBL] [Abstract][Full Text] [Related]
8. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 3',4',5'-trimethoxy evodiamine derivatives as potential antitumor agents.
Peng Y; Xiong R; Li Z; Peng J; Xie ZZ; Lei XY; He D; Tang G
Drug Dev Res; 2021 Nov; 82(7):1021-1032. PubMed ID: 33600007
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of artemyrianolide H derivatives as potential antihepatoma agents.
Li TZ; Yang XT; Ma WJ; Ma YB; Li FJ; Wang YC; Chen JJ
Bioorg Chem; 2023 Aug; 137():106617. PubMed ID: 37267793
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
Dai M; Yuan X; Kang J; Zhu ZJ; Yue RC; Yuan H; Chen BY; Zhang WD; Liu RH; Sun QY
Eur J Med Chem; 2013 Nov; 69():159-66. PubMed ID: 24013415
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME.
Zhu H; Ge K; Lu J; Jia C
Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1551-1560. PubMed ID: 31359090
[TBL] [Abstract][Full Text] [Related]
13. [YAP regulates the proliferation and modifies the sensitivity to sorafenib in hepatocellular carcinoma cells].
Guo LW; Shao GL; Luo J; Hao WY; Yao Z; Zheng JP
Zhonghua Zhong Liu Za Zhi; 2018 Nov; 40(11):818-823. PubMed ID: 30481931
[No Abstract] [Full Text] [Related]
14. Synthesis and biological evaluations of N'-substituted methylene-4-(quinoline-4-amino) benzoylhydrazides as potential anti-hepatoma agents.
Li B; Zhu F; He F; Huang Q; Liu X; Wu T; Zhao T; Qiu Y; Wu Z; Xue Y; Fang M
Bioorg Chem; 2020 Mar; 96():103592. PubMed ID: 32044517
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma.
Yang F; Shi L; Liang T; Ji L; Zhang G; Shen Y; Zhu F; Xu L
Biochem Biophys Res Commun; 2017 Mar; 485(1):54-61. PubMed ID: 28189683
[TBL] [Abstract][Full Text] [Related]
16. Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia.
Li YL; Zhang NY; Hu X; Chen JL; Rao MJ; Wu LW; Li QY; Zhang B; Yan W; Zhang C
Biochem Biophys Res Commun; 2018 Apr; 498(3):481-486. PubMed ID: 29505792
[TBL] [Abstract][Full Text] [Related]
17. Discovery of penipanoid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivatives as potential anticancer agents by inhibiting cell proliferation and inducing apoptosis in hepatocellular carcinoma cells.
Wang CJ; Guo X; Zhai RQ; Sun C; Xiao G; Chen J; Wei MY; Shao CL; Gu Y
Eur J Med Chem; 2021 Nov; 224():113671. PubMed ID: 34237623
[TBL] [Abstract][Full Text] [Related]
18. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
[TBL] [Abstract][Full Text] [Related]
19. Detailed studies on the anticancer action of rosmarinic acid in human Hep-G2 liver carcinoma cells: evaluating its effects on cellular apoptosis, caspase activation and suppression of cell migration and invasion.
Jin B; Liu J; Gao D; Xu Y; He L; Zang Y; Li N; Lin D
J BUON; 2020; 25(3):1383-1389. PubMed ID: 32862580
[TBL] [Abstract][Full Text] [Related]
20. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
